Opus Genetics, Inc. Additional Paid in Capital, Common Stock
Opus Genetics, Inc. (IRD) had Additional Paid in Capital, Common Stock of $173.54 million as of 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Balance Sheet › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2020-10-29
- 2020-09-30: Additional Paid in Capital, Common Stock $173.54M.
- 2020-06-30: Additional Paid in Capital, Common Stock $173.42M.
- 2020-03-31: Additional Paid in Capital, Common Stock $173.35M.
- 2019-12-31: Additional Paid in Capital, Common Stock $173.28M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2020-09-30 | $173.54M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $173.42M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $173.35M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $173.28M 10-Q · filed 2020-10-29 | |
| 2019-09-30 | $173.20M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $173.11M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $172.98M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $165.27M 10-K · filed 2020-02-21 | $165.26M 10-K · filed 2019-03-07 |
| 2018-09-30 | $158.01M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $157.72M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $157.45M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $157.14M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $151.86M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $151.61M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $137.78M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $132.09M 10-K · filed 2018-03-09 | $132.07M 10-K · filed 2017-02-24 |
| 2016-09-30 | $131.72M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $127.42M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $127.06M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $124.49M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $120.67M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $120.37M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $119.09M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $118.06M 10-K · filed 2016-03-14 | |
| 2014-09-30 | $117.87M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $117.64M 10-Q · filed 2014-08-13 | |
| 2014-03-31 | $115.45M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $85.45M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $79.96M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $73.47M 10-Q · filed 2013-08-12 | |
| 2013-03-31 | $73.23M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $72.86M 10-K · filed 2014-03-21 | |
| 2012-09-30 | $68.01M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $67.95M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $67.90M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $67.81M 10-K · filed 2013-03-22 | |
| 2011-09-30 | $67.67M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $67.50M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $56.16M 10-K · filed 2012-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |